Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants

References

• Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Nov;16(11):642–653.
   PubMed Web of Science ®Google Scholar
• Lambeir AM, Scharpé S, De Meester I. DPP4 inhibitors for diabetes–what next? Biochem Pharmacol. 2008 Dec 15; 76(12):1637–1643.
   PubMed Web of Science ®Google Scholar
• Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):479–486.
   PubMed Web of Science ®Google Scholar
• Shao S, Xu Q, Yu X, et al. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol Ther. 2020 May;209:107503.
   PubMed Web of Science ®Google Scholar
• Doupis J, Veves A. DPP4 inhibitors: a new approach in diabetes treatment. Adv Ther. 2008 Jul;25(7):627–643.
   PubMed Web of Science ®Google Scholar
• Yorifuji N, Inoue T, Iguchi M, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice. Oncol Rep. 2016 Feb;35(2):676–682.
   PubMed Web of Science ®Google Scholar
• Kawakubo M, Tanaka M, Ochi K, et al. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects. Sci Rep. 2020 Jan 22;10(1):983.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Wang TY, Liu CL, et al. Dipeptidyl peptidase IV as a prognostic marker and therapeutic target in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2017 Aug 1; 102(8):2930–2940.
   PubMed Web of Science ®Google Scholar
• Amritha CA, Kumaravelu P, Chellathai DD. Evaluation of anti cancer effects of DPP-4 inhibitors in colon cancer- an invitro study. J Clin Diagn Res. 2015 Dec;9(12):FC14–6.
   PubMedGoogle Scholar
• Hollande C, Boussier J, Ziai J, et al. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nat Immunol. 2019 Mar;20(3):257–264.
   PubMed Web of Science ®Google Scholar
• Ng L, Foo DC, Wong CK, et al. Repurposing DPP-4 inhibitors for colorectal cancer: a retrospective and single center study. Cancers (Basel). 2021 Jul 17;13(14):3588.
   PubMed Web of Science ®Google Scholar
• Gokhale M, Buse JB, Gray CL, et al. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diabetes Obes Metab. 2014 Dec;16(12):1247–1256.
   PubMed Web of Science ®Google Scholar
• Information for healthcare professionals - Acute pancreatitis and sitagliptin (marketed as januvia and janumet). [cited 2013 Apr 20th]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm
   Google Scholar
• Overbeek JA, Bakker M, van der Heijden AAWA, et al. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2018 Jul;34(5):e3004.
   PubMed Web of Science ®Google Scholar
• Dicembrini I, Nreu B, Montereggi C, et al. Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Acta Diabetol. 2020 Jun;57(6):689–696.
   PubMed Web of Science ®Google Scholar
• Lin C, Cai X, Yang W, et al. Glycemic control and the incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Endocrine. 2020 Nov;70(2):232–242.
   PubMed Web of Science ®Google Scholar
• Pinto LC, Rados DV, Barkan SS, et al. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep. 2018 Jan 15;8(1):782.
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011 Nov;27(3):57–64.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Enz N, Vliegen G, De Meester I, et al. CD26/DPP4 - a potential biomarker and target for cancer therapy. Pharmacol Ther. 2019 Jun;198:135–159.
   PubMed Web of Science ®Google Scholar
• Almagthali AG, Alkhaldi EH, Alzahrani AS, et al. Dipeptidyl peptidase-4 inhibitors: anti-diabetic drugs with potential effects on cancer. Diabetes Metab Syndr. 2019 Jan-Feb;13(1):36–39.
   PubMed Web of Science ®Google Scholar
• Busek P, Malík R, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol. 2004 Mar;36(3):408–421.
   PubMed Web of Science ®Google Scholar
• Cordero OJ, Rafael-Vidal C, Varela-Calviño R, et al. Distinctive CD26 expression on CD4 T-Cell subsets. Biomolecules. 2021 Oct 2; 11(10):1446.
   PubMed Web of Science ®Google Scholar
• Vangoitsenhoven R, Mathieu C, Van der Schueren B. GLP1 and cancer: friend or foe? Endocr Relat Cancer. 2012 Sep 5;19(5):F77–88.
   PubMed Web of Science ®Google Scholar
• Xie Y, Zhu S, Song X, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. Cell Rep. 2017 Aug 15;20(7):1692–1704.
   PubMed Web of Science ®Google Scholar
• Zheng X, Liu J, Li X, et al. Angiogenesis is promoted by exosomal DPP4 derived from 5-fluorouracil-resistant colon cancer cells. Cancer Lett. 2021 Jan 28;497:190–201.
   PubMed Web of Science ®Google Scholar
• Davies S, Beckenkamp A, Buffon A. CD26 a cancer stem cell marker and therapeutic target. Biomed Pharmacother. 2015 Apr;71:135–138.
   PubMed Web of Science ®Google Scholar
• Ohnuma K, Hatano R, Komiya E, et al. A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target. Front Biosci (Landmark Ed). 2018 Jun 1;23(9):1754–1779.
   PubMedGoogle Scholar
• Beckenkamp A, Davies S, Willig JB, et al. DPPIV/CD26: a tumor suppressor or a marker of malignancy? Tumour Biol. 2016 Jun;37(6):7059–7073.
   PubMed Web of Science ®Google Scholar
• Femia AP, Raimondi L, Maglieri G, et al. Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. Int J Cancer. 2013 Nov 15;133(10):2498–2503.
   PubMed Web of Science ®Google Scholar
• Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019 Dec;30:72–130.
   PubMed Web of Science ®Google Scholar
• Zheng M, Yoshimoto N, Muramatsu K, et al. Maculopapular drug eruption induced by linagliptin. Australas J Dermatol. 2018 Nov;59(4):e287–e288.
   PubMed Web of Science ®Google Scholar
• Psomadakis C, Shahzad N, Katz J. Linagliptin-associated blistering and ulceration. BMJ Case Rep. 2017 May 31;2017:bcr2017219998.
   Google Scholar
• Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol. 2019 Jun 4;10:1238
   PubMed Web of Science ®Google Scholar
• Yang W, Cai X, Zhang S, et al. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2021 Mar;37(3):e3391.
   PubMed Web of Science ®Google Scholar
• Kearney DE, Cauley CE, Aiello A, et al. Increasing incidence of left-sided colorectal cancer in the young: age is not the only factor. J Gastrointest Surg. 2020 Oct;24(10):2416–2422.
   PubMed Web of Science ®Google Scholar
• Balducci L. Management of cancer in the elderly. Oncology (Williston Park, N.Y.). 2006 Feb;20(2):135–143. discussion 144, 146, 151-2.
   PubMed Web of Science ®Google Scholar
• Carstensen B, Jørgensen ME, Friis S. The epidemiology of diabetes and cancer. Curr Diab Rep. 2014 Oct;14(10):535.
   PubMed Web of Science ®Google Scholar
• Pan R, Zhu M, Yu C, et al.; China Kadoorie Biobank Collaborative Group. Cancer incidence and mortality: a cohort study in China, 2008-2013. Int J Cancer. 2017 Oct 1;141(7):1315–1323.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015 Jul;95(3):727–748.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhang X, Ma Y, et al. Incident type 2 diabetes duration and cancer risk: a prospective study in two US cohorts. J Natl Cancer Inst. 2021 Apr 6; 113(4):381–389.
   PubMedGoogle Scholar
• Schrijnders D, Hendriks SH, Kleefstra N, et al. Sex differences in obesity related cancer incidence in relation to type 2 diabetes diagnosis (ZODIAC-49). PLoS One. 2018 Jan 25;13(1):e0190870.
   PubMed Web of Science ®Google Scholar
• Satija A, Spiegelman D, Giovannucci E, et al. Type 2 diabetes and risk of cancer. BMJ. 2015;2(350):g7707.
   Google Scholar
• Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: local and systemic mechanisms. Annu Rev Med. 2015;66(1):297–309.
   PubMedGoogle Scholar
• Mauvais-Jarvis F. Gender differences in glucose homeostasis and diabetes. Physiol Behav. 2018 Apr 1; 187:20–23
   PubMed Web of Science ®Google Scholar
• Bansal D, Bhansali A, Kapil G, et al. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013 Jun;16(2):151–8, S1.
   PubMed Web of Science ®Google Scholar
• Noto H, Tsujimoto T, Noda M. Significantly increased risk of cancer in diabetes mellitus patients: a meta-analysis of epidemiological evidence in Asians and non-Asians. J Diabetes Investig. 2012 Feb 20; 3(1):24–33.
   PubMed Web of Science ®Google Scholar